- Healthcare Professionals
- Research
- Clinical trials
- Fusion Pharmaceuticals
2024-12-05T00:00:00.000+00:00
Ongoing
Fusion Pharmaceuticals
Fusion Pharmaceuticals
Chronic Lymphocytic Leukaemia
A phase 2, open-label, multi-centre study of FPI-2265 (225Ac-PSMA-I&T) and olaparib in participants with metastatic castration-resistant prostate cancer (mCRPC).
A phase 2, open-label, multi-centre study of FPI-2265 (225Ac-PSMA-I&T) and olaparib in participants with metastatic castration-resistant prostate cancer (mCRPC).
Trial overview
Disease
Prostate cancer
Topic
Interventional
Sponsor
Fusion Pharmaceuticals
Description
A phase 2, open-label, multi-centre study of FPI-2265 (225Ac-PSMA-I&T) and olaparib in participants with metastatic castration-resistant prostate cancer (mCRPC).
Study details
Trial status
Opening Spring 2025
Principal Investigator

